Date: June 11th 2025

Re: Invitation to OTI's Bridge Funding & Milestone Update.

To: OTI Strategic Taskforce Advisors, Friends and Colleagues

Dear Esteemed Mentors, Advisors, Friends and Colleagues,

Season's change brings new hope and new perspective. I am thankful for your being a part of OTI's journey and of our story that is shaping glaucoma and medicine development. After three-year *bootstrapping* in business, OTI LLC has emerged as the leader that is creating the new MMP (matrix metalloproteinase) platform therapy for curing glaucoma blindness. We are setting new standards of glaucoma disease management from IOP reduction to IOP normalization.

OTI-2024 is built upon 14-year Inotek Pharma's work on Trabodenoson- an IOP lowering drug (symptom relief) to have become the first curative solution for treating *refractory glaucoma (poor responders) and stopping the neural degeneration* in patients with glaucoma. Under the new MMP patent territory, OTI-2024 is positioned as a **dual action** glaucoma drug and a new MMP agent, which has the potential to replace the PG drug dominance (60%) in the past 30 years, as the first line therapy for all types of glaucoma and all stages of glaucoma. OTI-2024 is the first tissue rejuvenation drug, can reverse the aging tissue (trabecular meshwork) that causes glaucoma blindness. OTI-2024 (1.5%) is anticipated to capture 60% glaucoma drug market size among $11.5B global glaucoma market by 2023 (estimate).

- Dr. James Tsai, President of NEEI, recently joined OTI SAB, noted: "our goal is to position OTI-2024 as a MMP therapeutic agent with long-term TM benefits with modulation of any IOP fluctuations and less need for consistent adherence to medication use".
- Dr. Ike Ahmed, a pioneer of glaucoma MIGS surgery, advised us on Phase 3 endpoint design, we now have two different primary endpoints to support two different indications: IOP reduction @ 3 months and HVF @16 months, if it is approved (likely), OTI-2024 (1.5%) will be the Only glaucoma drug that can lower the IOP and preserve the vision health.
- OTI is at a pre-series A financing stage, has a derisked, patented Phase 3 glaucoma neural protection asset, the next step dev. is to complete a planned Phase 3 clinical trial of OTI-2024 in a new simple eye drop formulation (1.5%).

Herein I like to invite you to invest in OTI's bridge funding (a gap) to the Series A. This is **an equity-based Private Placement by Invitation**, offering to OTI's inner circle advisors, friends, family, colleagues who has been a part of OTI's journey and wish to invest in this amazing opportunity. **The target goal is to raise $250K. The price is $5 per unit, minimal of $25K per individual, closes by 6/30/2025**. The funds will be used for OTI's patent national phase filings, legal fees, and SG&A costs. Details please see above attached **Executive Summary -OTI's Bridge Funding** (Advised by Mr. Andrew Merken, Corporate Attorney, Shareholder at Polsinelli LLP).

~ Milestones Achieved Under OTI LLC since July 2022 ~

1. **IPs/Patent Progress:**
    a) OTI filed 4 provisional patents and 2 PCTs. Both PCT #1 and PCT # 2 received positive written opinions from patent office, confirming the novelty of key claims that protects

optimal dosing and MMP platform therapy with 20-year market exclusivity, including OTI-2024 eye drops and sustained release implant products. **OTI-2024 is a new chemical entity (NCE) under OTI's new patent territoy.** *There is no prior approved indication of this compound.*

b) PCT #1 has completed the national phase filings on March 2025 with 6 jurisdictions: US, EU, Canada, Australia, Japan, China and India, three major markets.
c) The PCT #2 Published on May 1st 2025.
d) Inventor: Tina Guanting Qiu, company founder/CEO. OTI owns 100% new patent portfolio.
e) OTI conducted due diligence on "old" patents filed by Inotek Pharma (expired), has concluded that these old patents hold no commercial values.

2. **FDA Progress:** OTI submitted a formal investigator-based New IND application on August 19 2024 (P171507) under FDA real world evidence policy), obtained **505(b)(2)** regulatory pathway for approval with the hVF endpoint at 12-18 months, tentatively agreed by FDA. OTI submitted a breakthrough therapy designation to FDA, pending for the CMC and additional 6-month Ocular toxicity study for the new formulation to open the new IND.
3. **Strategic business decision**: following FDA on P171507 IND review meeting (Oct 2024), OTI made the decision to reformulate the compound in a simple eye drop formulation, and forgo Inotek's old eye drop formulation (IP expired), subsequently, OTI made *No-Go* to Rocket/Inotek with regarding of the "old" IND (outdated).
4. **Freedom to Operate:** OTI owns 100% MMP patent and new IND data package (synthetic from published data), has the freedom to operate, no upfront payment, equity/royalty to be paid to any 3rd party. Cap Table is attractive to investors.
5. **Team Building:** Scientific Medical SAB Team: Since April 2024, OTI has onboarded three Top glaucoma surgeon and clinical medical experts **Dr. Louis Cantor, Dr Ike Ahmed, Dr James Tsai. Prof Clive Wilson** (UK).
6. **Product development** & Drug Delivery formulation candidate selection (completed): OTI has conducted thorough risk/benefit analysis on formulation selection, made strategic decision to reformulate OTI-2024 in a simple standard eye drop; Prioritize eye drops product whilst exploring out-licensing the IP of SR product to companies with proprietary delivery technology. These exercises significantly reduced the product dev risks and shorten timeline to market (to 5 years).
7. **Partnerships (reformulation)**: 1)IND enabling: OTI has established agreement with Regis Tech (IL) as API manufacture partner, and the SOWs with Integral Biosystem (MA) as formulation partner. Both have deep expertise and experience of working on Trabodenoson prior. This is the 3rd clinical formulation of the same compound (low risk, cost effective)
8. **Exit via Partnership:** OTI has outreached to the key OPH players (Alcon, B&L, Allergan, Bayer, Regeneron, Genentech, Ocular Therapeutic, Glaukos).
9. OTI also has two retinal discovery pipelines via drug repurposing and new formulation.